Cytokinetics ( NASDAQ: CYTK ) is scheduled to announce Q2 earnings results on Thursday, August 8th, after market close. The consensus EPS Estimate is -$0.91 and the consensus Revenue Estimate is $20.
96M (+2309.2% Y/Y). Over the last 3 months, EPS estimates have seen 9 upward revisions and 2 downward.
Revenue estimates have seen 3 upward revisions and 1 downward. More on Cytokinetics Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes Cytokinetics Decides To Go It Alone Cytokinetics says potential acquirer walked away Cytokinetics drops after pricing public offering, debt deal; brokerages cut PT Seeking Alpha’s Quant Rating on Cytokinetics.
